Dicerna Pharmaceuticals Inc Company News


Old Arcived News About Dicerna Pharmaceuticals Inc

  • 4:06 pm Dicerna Pharmaceuticals reports continued progress in the clinical development of DCR-MYC; plans to report proof-of-concept data in 2H16.
  • Dicerna Announces Addition to NASDAQ Biotechnology Index. [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of RNA interference therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index , effective upon market open on December 21, 2015.
  • Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results.
  • Dicerna Announces Third Quarter 2015 Financial and Operational Results. [at noodls] - 425422cf-bd93-4e39-8914-9c5ba2fc2692.pdf November 10, 2015 -Management to Host Conference Call Today at 4:30 pm ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader ...
  • Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1. [at noodls] - e46a2477-48d7-436f-811a-60ab80d21835.pdf December 21, 2015 - Company Expects to Initiate Phase 1 Trial in Patients with PH1 in Early 2016 - - Ongoing Observational Study Measures Biomarkers Implicated ...
  • Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers.
  • Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer. [at noodls] - 80fde566-f1ba-400b-ba0e-21bdd8ed3491.pdf December 15, 2015 Dicerna Pharmaceuticals Appoints John 'Jack' Green Interim Chief Financial Officer CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, ...
  • Dicerna Pharmaceuticals Appoints John “Jack” Green Interim Chief Financial Officer. [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of RNA interference therapeutics, today announced the appointment of John “Jack” Green as interim chief financial officer , effective January 1, 2016.
  • Dicerna Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today.
  • DICERNA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E.
  • DICERNA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a.
  • DICERNA PHARMACEUTICALS INC Financials.
  • Dicerna Pharmaceuticals posts 3Q loss.
  • Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).
  • Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates.
  • Dicerna to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10, 2016.
  • Dicerna to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 10, 2015.
  • Dicerna to Present at the 2016 Leerink Partners Global Healthcare Conference.
  • Dicerna to Present at Two March Conferences.
  • Dicerna to Present at Two November Conferences. [at noodls] - 9deb8e7f-c96a-4c6a-ba5c-f9788107c9f2.pdf November 13, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, ...
  • Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors. [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today reported continued progress in the clinical development of DCR-MYC, Dicerna's investigational Dicer substrate short interfering RNA therapeutic designed to silence MYC, an oncogene implicated in multiple tumor types.
  • Edited Transcript of DRNA earnings conference call or presentation 10-Nov-15 9:30pm GMT.
  • Hedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc Short Company Overview:

Dicerna Pharmaceuticals, Inc. provides biopharmaceutical products. The Company discovers and develops ribonucleic acid for the treatment of liver diseases and cancer.